|
|
Upfront Briefing
Monday had one loud message: Vertex is done being a cystic-fibrosis one-trick. It dropped $10B — a 102% premium and its biggest check ever — to buy Crinetics and its acromegaly franchise, sending CRNX up triple digits after the bell.
Brussels chipped in, clearing Genmab and AbbVie's Tepkinly bispecific combo in follicular lymphoma. And CMS reopened the 340B wound with a proposed ~40% cut to hospital drug payments — because nothing says summer like a $4.55B reimbursement haircut.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,537.4 |
0.7% |
9.9% |
| Nasdaq 100 |
29,697.9 |
1.3% |
17.8% |
| Russell 2000 |
3,009.5 |
0.4% |
20.0% |
| Healthcare (XLV) |
162.0 |
(1.1%) |
4.1% |
| Biotech (XBI) |
160.8 |
0.2% |
32.3% |
| Nasdaq Biotech (NBI) |
6,744.8 |
(0.3%) |
18.2% |
| Clinical Trials (BBC) |
52.8 |
0.0% |
40.3% |
|
- Healthcare lagged a green tape — XLV −1.1% and NBI −0.3% against XBI +0.2% — with Amgen (−2.3%) and Merck (−2.1%) the drag, even as Vertex's $10B swoop on Crinetics sent CRNX up triple digits after hours.
- The broad rally was a chip/AI bid: Nasdaq 100 +1.3% and the Dow to a record above 53,000, led by AMD (+6.6%) and Broadcom after Foxconn's strong sales signaled sustained AI demand, with Samsung's Q2 print due Tuesday.
- Market data: U.S. cash close Monday, 6 July 2026.
The Big 3
|
1
|
Vertex to acquire Crinetics for $10 billion
|
- Vertex is buying Crinetics for ~$10B ($85/share, 102% premium) — its largest acquisition ever — adding the acromegaly drug Palsonify (paltusotine) and a Phase 3 CAH candidate, atumelnant.
- Why it matters: At $85 a share — a 102% premium and Vertex's largest deal ever — this is a scale bet on commercial rare-endocrine revenue, not a pipeline flyer. Vertex picks up Palsonify, the first oral acromegaly therapy, plus atumelnant in Phase 3 for congenital adrenal hyperplasia; management guides to $5B-plus combined peak sales, accretion by 2029, and a Q3 close backed by a $4.5B BofA/Morgan Stanley bridge. Endocrine developers just got a fresh 100%-premium takeout marker, and Vertex confirms it will pay up to diversify beyond CF and Journavx. It lands alongside AbbVie/Apogee and Sun/Organon among the year's biggest biopharma deals.
- Source: STAT
- More: Endpoints
|
|
2
|
EC clears Genmab/AbbVie's Tepkinly combo in follicular lymphoma
|
- The European Commission approved Tepkinly (epcoritamab) plus lenalidomide and rituximab for second-line relapsed/refractory follicular lymphoma — the first bispecific-based combo cleared in Europe for the setting.
- Why it matters: The EC cleared Tepkinly plus R2 for second-line relapsed/refractory follicular lymphoma — the first bispecific-based combo approved in Europe for the setting, and chemo-free. EPCORE FL-1 (n=488) is the case: a 79% cut in progression-or-death risk (HR 0.21), 96% ORR versus 81%, and 74% complete responses versus 38% against R2 alone — the first Phase 3 showing a bispecific-containing regimen beats R2 here. That randomized bar outclasses the single-arm data behind Roche's Lunsumio, the incumbent 2L bispecific in EU FL. For GMAB and ABBV it deepens the epcoritamab franchise beyond DLBCL; watch CRS (serious adverse reactions in 44%) as the commercial ramp begins.
- Source: BioPharm International
- More: Genmab AbbVie
|
| 3 | CMS proposes a ~40% cut to 340B drug payments |
- CMS's draft CY2027 outpatient rule would drop Medicare Part B payment for 340B-acquired drugs from ASP+6% to ASP−33.4% and accelerate the $7.8B clawback, pulling billions from hospital outpatient revenue.
- Why it matters: CMS's draft CY2027 outpatient rule would cut Medicare Part B payment for 340B-acquired drugs from ASP+6% to ASP−33.4% — near a 40% reduction — and accelerate the $7.8B clawback by lifting the conversion-factor offset from 0.5% to 3%, closing recoupment in 2029 rather than 2041. First-year drug-payment savings: $4.55B across roughly 3,500 hospitals. For 340B-heavy health systems it's a direct revenue hit; the AHA calls the cut unlawful, echoing the 2018 reduction the Supreme Court voided in 2022. For manufacturers fighting 340B contract-pharmacy expansion — Lilly among them — a tighter program cuts the other way. Comments run to Aug 31; litigation risk is high.
- Source: Fierce Healthcare
|
Everything Else that broke
- FDA cleared 23 new drugs in the first half, easing some staffing-driven timing angst. — Fierce Pharma
- Genentech licensed Astex's preclinical breast-cancer (cell-cycle) discovery program — $25M upfront, up to $490M in milestones plus tiered royalties — and disclosed 103 layoffs tied to its gRED restructuring. — Fierce Biotech
- Two PDUFA decisions land today: AZ/Daiichi's Enhertu in HER2+ early breast cancer (post-neoadjuvant) and Vera Therapeutics' atacicept in IgA nephropathy. — FDA calendar
- AMO Pharma said AMO-02's registrational study will use hospitalization as the primary endpoint. — PR
- Neuphoria's Phase II Alzheimer's miss cast fresh doubt on its CHRNA7 program. — BioCentury
- Roche previewed AAIC data spanning trontinemab and Elecsys pTau217 and pTau181 blood tests. — PR
- CDER named longtime GLP-1 reviewer Lisa Yanoff acting deputy director. — FDA
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Vertex is buying Crinetics for $10B (see The Big 3). — STAT
- ICYMI: Novartis is buying Myricx for $1.1B upfront (up to $1.5B) for a preclinical NMTi ADC payload platform. — BioPharma Dive
- Genentech/Astex — exclusive license to Astex's breast-cancer cell-cycle discovery program; $25M upfront, up to $490M milestones plus tiered royalties (preclinical). — Fierce Biotech
- GTCR agreed to sell Corza Medical's Biosurgery unit to EQT. — PR
VC / Private Financings
- Ona Therapeutics raised $86.6M in Series B to advance its ADC pipeline; investors included Columbus Venture Partners, Mérieux Equity Partners, COFIDES, Korys, Alta Life Sciences, Asabys Partners, Bpifrance, CDTI, FundPlus NV and Ysios Capital. — Fierce Biotech
IPOs / Follow-Ons
- Abivax closed its upsized $920M public offering ($874.1M net; ~9.2% dilution), extending runway toward obefazimod's UC/Crohn's programs. — PR
- Scribe Therapeutics filed for a Nasdaq IPO (S-1 filed July 2; shares/pricing TBD) to fund its CRISPR-based PCSK9 gene silencer STX-1150 — now in a first-in-human LDL-C study in Australia (up to 64 patients, topline 1H27) — plus LPA (TX-1200) and APOC3 (STX-1400) programs. — Fierce Biotech
- Nuvation Bio upsized its convertible senior notes offering to $287.5M after the greenshoe was fully exercised. — PR
- Elicio Therapeutics closed a $15M registered direct offering to help fund ELI-002 7P's planned Phase 1 work. — PR
Academic Corner - HuR degrader knocks down BRAF in cancer. — Nature RDD
|
Vertex went shopping, Brussels signed off, and 340B hospitals went pale — that's a Tuesday. See you tomorrow. — BioBucks Team
|
|
|
